Physician profile
Ella Glaser
NPI 1841852647
$14,282.47
in general payments reported to CMS, 2019-2025
30 companies · $3,989 in 2025
The $3,989 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $510 · 2021: $1,406 · 2022: $2,173 · 2023: $2,942 · 2024: $3,165 · 2025: $3,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,020 · Honoraria: $1,950 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,020.35 |
| Honoraria | $1,950.00 |
| Education | $125.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $2,033.41 | 2025 | Zelsuvmi |
| Abbvie INC. | $2,019.05 | 2021-2025 | |
| Janssen Biotech, INC. | $1,348.97 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $1,312.99 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,059.11 | 2020-2025 | Arazlo, Siliq, Jublia |
| Genzyme Corporation | $990.09 | 2021-2025 | |
| Galderma Laboratories, L.P. | $688.32 | 2020-2025 | Dysport, Aklief |
| Amgen INC. | $614.16 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $589.68 | 2020-2025 | |
| Incyte Corporation | $542.96 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $461.73 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $358.47 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $314.59 | 2020-2025 | Dupixent, Libtayo |
| Ucb, INC. | $303.89 | 2022-2024 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $302.89 | 2023-2024 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $273.62 | 2022 | |
| Allergan, INC. | $259.83 | 2019-2022 | |
| Pfizer INC. | $193.28 | 2020-2023 | |
| Vyne Pharmaceuticals INC. | $149.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.45 | 2022-2024 | Spevigo |
| Leo Pharma INC. | $80.22 | 2025 | Anzupgo |
| Botanix Sb INC | $71.53 | 2025 | Sofdra |
| Almirall LLC | $45.54 | 2024-2025 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $36.23 | 2025 | |
| Journey Medical Corporation | $33.21 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $25.39 | 2024 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $20.64 | 2023 | Valchlor |
| Solta Medical, A Division of Bausch Health US, LLC | $19.39 | 2024 | Clear+Brilliant |
| Genentech, INC. | $18.77 | 2023 | Erivedge |
| Biofrontera INC. | $10.91 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.